Journal of Urban Health

, Volume 77, Issue 3, pp 331–345 | Cite as

Methadone treatment and hiv and hepatitis band C risk reduction among injectiors in the seattle area

  • Hanne Thiede
  • Holly Hagan
  • Christopher S. Murrill
Original Articles: Substance Use and HIV Prevention

Abstract

Drug treatment has the potential to reduce incidence of blood-borne infections by helping injection drug users (IDUs) achieve abstinence or by decreasing the frequency of injection and sharing practices. We studied the associations between retention in methadone treatment and drug use behaviors and incidence of hepatitis B and C in a cohort of IDUs in the Seattle, Washington, area. Data on IDUs entering methadone treatment at four centers in King County, Washington, were collected through face-to-face interviews using a standardized questionnaire at baseline and 12-month follow-up between October 1994 and January 1998. Blood specimens were obtained and tested for human immunodeficiency virus (HIV) and hepatitis B and C. Drug treatment status at follow-up was analyzed in relation to study enrollment characteristics and potential treatment outcomes, including injection risk behaviors, cessation or reduced frequency of injection, and incidence of hepatitis B and C. Of 716 IDUs, 292 (41%) left treatment, 198 (28%) disrupted (left and returned) treatment, and 226 (32%) continued treatment throughout the 1-year follow-up period. Compared to those who left treatment, subjects who disrupted or continued were less likely to inject at follow-up (odds ratio [OR]=0.5, 95% CI 0.3-0.7; and, OR=0.1, 95% CI 0.1-0.2, respectively). Among the 468 (65%) subjects who continued injecting, those who continued treatment injected less frequently, were less likely to pool money to buy drugs (OR=0.5, 95% CI 0.3-0.8) and inject with used needles (OR=0.5, 95%, CI 0.2-0.8) compared to those who left treatment. Cooker or cotton sharing was not associated with retention in treatment, but hepatitis B incidence was lowest among those who continued treatment. The results of this study suggest drug use risk reduction is more likely to be achieved by those who remain in drug treatment and by those who stop injecting, but that those who drop out and return and those who continue to inject while in treatment may also benefit. This supports the role of consistent drug treatment in an overall harmreduction strategy.

Key words

HBV HCV HIV Injection Drug Use Methadone Treatment Prevention 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Centers for Disease Control and Prevention.HIV/AIDS Surveillance Report. Atlanta, GA: Centers for Disease Control and Prevention; 1998;10(2).Google Scholar
  2. 2.
    Joint United Nations Programme on AIDS (UNAIDS).Report on the Global HIV/AIDS Epidemic. Geneva, Switzerland: World Health Organization; 1998.Google Scholar
  3. 3.
    Des Jarlais DC, Marmor M, Friedman P, et al. HIV incidence among injection drug users in New York City, 1992–1997: evidence for a declining epidemic.Am J Public Health. 2000;90:352–359.PubMedGoogle Scholar
  4. 4.
    Des Jarlais DC, Perlis T, Friedman SR et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996.Am J Public Health. 1998;88:1801–1806.PubMedGoogle Scholar
  5. 5.
    Crofts N, Aitken CK. Incidence of bloodborne viral infections and risk behaviours in a cohort of injecting drug users in Victoria, 1990–1995.Med J Aust. 1997;167:17–20.PubMedGoogle Scholar
  6. 6.
    van Ameijden EJC, van den Hoek AJAR, Coutinho RA. Injecting risk behaviors among drug users in Amsterdam 1986 to 1992, and its relationship to AIDS prevention programs.Am J Public Health. 1994;84:275–281.PubMedGoogle Scholar
  7. 7.
    Beardsley M, Deren S, Tortu S, Goldstein MF, Ziek K, Hamid R. Trends in injection risk behaviors in a sample of New York City injection drug users: 1992–1995.J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:283–289.PubMedGoogle Scholar
  8. 8.
    Longshore D, Annon J, Anglin MD. Long-term trends in self-reported HIV risk behavior: injection drug users in Los Angeles, 1987 through 1995.J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:64–72.PubMedGoogle Scholar
  9. 9.
    Hunter GM, Donoghoe MC, Stimson GV, Rhodes T, Chalmers CP. Changes in the injecting risk behaviour of injecting drug users in London, 1990–1993.AIDS. 1995;9:493–501.PubMedGoogle Scholar
  10. 10.
    Rezza G, Sagliocca L, Zaccarelli M, Nespoli M, Siconolfi M, Baldassarre C. Incidence rate and risk factors for HCV seroconversion among injection drug users in an area with low HIV seroprevalence.Scand J Infect Dis. 1996;28:27–29.PubMedGoogle Scholar
  11. 11.
    van Beek I, Dwyer R, Dore GJ, Luo K, Kaldor JM. Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.BMJ. 1998;317:433–437.PubMedGoogle Scholar
  12. 12.
    Wells EA, Calsyn DA, Clark LL. Retention in methadone maintenance is associated with reductions in different HIV risk behaviors for women and men.Am J Drug Alcohol Abuse. 1996;22:509–521.PubMedGoogle Scholar
  13. 13.
    Stark K, Müller, Bieenzle U, Guggenmoos-Holtzman I. Methadone maintenance treatment and HIV risk-taking behaviour among injecting drug users in Berlin.J Epidemiol Community Health. 1996;534–537.Google Scholar
  14. 14.
    MacGowan RJ, Brackbill RM, Rugg DL, et al. Sex, drugs and HIV counseling and testing: a prospective study of behavior-change among methadone-maintenance clients in New England.AIDS. 1997;11:229–235.CrossRefPubMedGoogle Scholar
  15. 15.
    Caplehorn JRM, Ross MW. Methadone maintenance and the likelihood of risky needlesharing.Int J Addict. 1995;30:685–698.PubMedGoogle Scholar
  16. 16.
    Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up.J Acquir Immune Defic Syndr Hum Retrovirol. 1993;6:1049–1056.Google Scholar
  17. 17.
    Baker A, Kochan N, Dixon J, Wodak A, Heather N. HIV risk-taking behaviour among injection drug users currently, previously and never enrolled in methadone treatment.Addiction. 1995;90:545–554.CrossRefPubMedGoogle Scholar
  18. 18.
    Calsyn DA, Saxon AJ, Wells EA, Greenberg DM. Longitudinal sexual behavior changes in injecting drug users.AIDS. 1992;6:1207–1211.PubMedGoogle Scholar
  19. 19.
    Hartel DM, Schoenbaum EE. Methadone treatment protects against HIV infection: two decades of experience in the Bronx New York City.Public Health Rep. 1998;113(suppl 1) 107–115.PubMedGoogle Scholar
  20. 20.
    Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985–1990.AIDS. 1994;8:223–231.PubMedGoogle Scholar
  21. 21.
    Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention.Public Health Rep. 1998;113(suppl 1):97–106.PubMedGoogle Scholar
  22. 22.
    Selvey LA, Denton M, Plant AJ. Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: factors influencing hepatitis C serostatus.Aust N Z J Public Health. 1997;21:102–104.PubMedGoogle Scholar
  23. 23.
    Crofts N, Luciano N, Oman K, Stevenson E, Sherman J. Methadone maintenance and hepatitis C virus infection among injecting drug users.Addiction. 1997;8:999–1005.Google Scholar
  24. 24.
    Des Jarlais DC, Paone D, Milliken J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial.Lancet. 1999;353:1657–1661.CrossRefPubMedGoogle Scholar
  25. 25.
    Hagan H, Thiede H, Weiss N, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C virus incidenceAm J Public Health. In press.Google Scholar
  26. 26.
    National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction.JAMA. 1998;280:1936–1943.Google Scholar
  27. 27.
    Seers KL, Delucci KL, Masson C, et al. Methadone maintenance versus 180-day psychosocially enriched detoxification for treatment of opioid dependence.JAMA. 2000;283:1303–1310.Google Scholar
  28. 28.
    Koester S, Anderson K, Hoffer L. Active heroin injectors' perceptions and use of methadone maintenance: cynical performance or self-prescribed risk reduction?Subst Use Misuse. 1999;34:2135–2153.PubMedGoogle Scholar
  29. 29.
    Lamagni TL, Davison KL, Hope VD. Poor hepatitis B vaccine coverage in injecting drug users: England, 1995 and 1996.Commun Dis Public Health. 1999;3:174–177.Google Scholar

Copyright information

© The New York Academy of Medicine 2000

Authors and Affiliations

  • Hanne Thiede
    • 1
    • 2
  • Holly Hagan
    • 1
    • 2
  • Christopher S. Murrill
    • 1
  1. 1.Public Health-Seattle-King CountyUSA
  2. 2.Department of EpidemiologyUniversity of WashingtonUSA

Personalised recommendations